Belus Jennifer M, Regenauer Kristen S, Hutman Elizabeth, Rose Alexandra L, Burnhams Warren, Andersen Lena S, Myers Bronwyn, Joska John A, Magidson Jessica F
Swiss Tropical and Public Health Institute, Department of Medicine, Basel, Switzerland.
University of Basel, Basel, Switzerland.
Drug Alcohol Depend Rep. 2022 Feb 26;2:100035. doi: 10.1016/j.dadr.2022.100035. eCollection 2022 Mar.
Despite efforts to detect and treat problematic substance use (SU) among people living with HIV (PLWH) in South Africa, integration of HIV and SU services is limited. We sought to understand whether PLWH and problematic SU were: (a) routinely referred to SU treatment, a co-located Matrix clinic, (b) used SU treatment services when referred, and (c) the individual amount spent on SU.
Guided by the RE-AIM implementation science framework, we examined patient-level quantitative screening and baseline data from a pilot clinical trial for medication adherence and problematic SU. Qualitative data came from semi-structured interviews with HIV care providers ( = 8), supplemented by patient interviews ( = 15).
None of the screened patient participants ( = 121) who were seeking HIV care and had problematic SU were engaged in SU treatment, despite the freely available co-located SU treatment program. Only 1.5% of the enrolled patient study sample ( = 66) reported lifetime referral to SU treatment. On average, patients with untreated SU spent 33.3% (=34.5%) of their monthly household income on substances. HIV care providers reported a lack of clarity about the SU referral process and a lack of direct communication with patients about patients' needs or interest in receiving an SU referral.
SU treatment referrals and uptake were rare among PLWH reporting problematic SU, despite the high proportion of individual resources allocated to substances and the co-located Matrix site. A standardized referral policy between the HIV and Matrix sites may improve communication and uptake of SU referrals.
尽管南非致力于在感染艾滋病毒的人群(PLWH)中检测和治疗有问题的物质使用(SU)情况,但艾滋病毒和物质使用服务的整合仍然有限。我们试图了解PLWH和有问题的SU是否:(a)被常规转介到物质使用治疗机构,即同一地点的美沙酮诊所;(b)在被转介后是否使用物质使用治疗服务;以及(c)在物质使用上的个人支出情况。
在RE-AIM实施科学框架的指导下,我们检查了一项关于药物依从性和有问题的物质使用的试点临床试验中患者层面的定量筛查和基线数据。定性数据来自对艾滋病毒护理提供者的半结构化访谈(n = 8),并辅以患者访谈(n = 15)。
尽管有免费的同一地点的物质使用治疗项目,但在寻求艾滋病毒护理且有问题的物质使用的筛查患者参与者(n = 121)中,没有一人参与物质使用治疗。在登记的患者研究样本(n = 66)中,只有1.5%的人报告有过转介到物质使用治疗的经历。平均而言,未接受治疗的物质使用患者将其每月家庭收入的33.3%(=34.5%)用于购买相关物质。艾滋病毒护理提供者表示,物质使用转介流程不明确,且未就患者接受物质使用转介的需求或兴趣与患者进行直接沟通。
在报告有问题的物质使用的PLWH中,物质使用治疗转介和接受情况很少见,尽管用于购买相关物质的个人资源比例很高,且有同一地点的美沙酮诊所。艾滋病毒和美沙酮诊所之间的标准化转介政策可能会改善沟通并提高物质使用转介的接受率。